Podcast: Download (Duration: 1:03 — 1.5MB)
Subscribe: RSS
Aducanumab or Aduhelm is a newly approved medicine for treating Alzheimer’s disease, with many experts asserting that it should never have gotten FDA approval. Caleb Alexander, an internal medicine expert at Johns Hopkins and a member of the FDA review …
Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Aduhelm is the proprietary name for aducanumab, a just approved medication for treatment of Alzheimer’s disease. Caleb Alexander, an internal medicine expert at Johns Hopkins, sat on the FDA review board for this medicine and explains why he voted no …
Should a new Alzheimer’s drug have been approved by the FDA? Elizabeth Tracey reports Read more →
Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
The longer someone has had diabetes the greater the chance they’ll develop dementia, a recent study of thousands over 30 years of follow up has shown. Rita Kalyani, a diabetes expert at Johns Hopkins, says while associations between diabetes and …
How are diabetes and dementia related? Elizabeth Tracey reports Read more →
Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Anchor lead: Are new drug trial results meaningful in Alzheimer’s disease? Elizabeth Tracey reports A new drug that clears something called amyloid from the brain may delay progression of Alzheimer’s disease, recently released data indicate. Constantine Lyketsos, an Alzheimer’s disease …
Podcast: Download (Duration: 1:05 — 1.5MB)
Subscribe: RSS
Anchor lead: How often is someone with dementia overmedicated? Elizabeth Tracey reports Polypharmacy refers to someone taking a multitude of medicines, with a recent study demonstrating that in people with dementia, polypharmacy with drugs that affect the brain occurs in …
